Future trends in combination of DTx with drugs and devices in hybrid therapies Future Trends in Combination of DTx with Drugs and Devices in Hybrid Therapies The healthcare landscape is undergoing a dramatic transformation with the incorporation of digital therapeutics (DTx), artificial intelligence (AI), and medical devices in hybrid therapies. As these technologies advance, regulators are faced with the task of establishing frameworks that ensure patient safety and efficacy. This article serves as a comprehensive guide for regulatory, clinical, and quality leaders in navigating the complexities of clinical evaluation and validation of DTx, particularly as they relate to the combination…

<!– Using RWE to Expand Indications and Labels for Approved DTx Products Digital Health & AI Regulation Clinical Evaluation & Validation of Digital Therapeutics (DTx) clinical evaluation validation digital therapeutics DTx DTx trials,effectiveness endpoints,usability validation,behavioural interventions,post market monitoring –> Using RWE to Expand Indications and Labels for Approved DTx Products Digital therapeutics (DTx) have transformed healthcare delivery through their ability to leverage technology for therapeutic interventions. Channelling Real-World Evidence (RWE) enables manufacturers to better understand their products’ effectiveness post-market and facilitates expanding indications and labels of approved products. This article provides a structured regulatory tutorial for successfully navigating the complex…

Governance for clinical safety oversight in digital therapeutics companies Governance for Clinical Safety Oversight in Digital Therapeutics Companies The rapid emergence of digital therapeutics (DTx) has indicated the efficacy and value of clinical evaluation validation within the health sector. As healthcare systems globally evolve, the governance surrounding clinical safety oversight in DTx becomes paramount, particularly for leaders in digital health, regulation, and clinical quality. This comprehensive guide serves as an actionable framework for ensuring compliance and safeguarding public health. 1. Understanding Digital Therapeutics Digital therapeutics, or DTx, encompass evidence-based therapeutic interventions driven by software to prevent, manage, or treat medical…

Post Market Effectiveness Monitoring Strategies for Digital Therapeutics (DTx) As digital therapeutics (DTx) continue to evolve, regulatory authorities such as the US FDA have established frameworks to ensure that these innovative solutions not only comply with safety standards but also provide efficacy in their intended use. This tutorial outlines step-by-step post-market effectiveness monitoring strategies for DTx, focusing on clinical evaluation and validation, essential for the success and sustainability of digital health interventions. Understanding Digital Therapeutics and Their Regulatory Landscape Digital therapeutics represent a powerful intersection of technology and healthcare, offering evidence-based therapeutic interventions driven by software. While DTx can serve…

Global HTA and Payer Perspectives on Evidence for Digital Therapeutics The rapid advancement in digital therapeutics (DTx) has prompted an increased focus on regulatory frameworks and health technology assessment (HTA) processes in the United States, United Kingdom, and European Union. Digital therapeutics are evidence-based therapeutic interventions delivered through software, targeting various conditions with a view towards improving patient outcomes. This article serves as a comprehensive step-by-step guide for digital health developers, regulatory professionals, and clinical leaders working with DTx as they navigate the complexities of clinical evaluation and validation. Understanding the Regulatory Landscape for Digital Therapeutics The regulatory landscape concerning…